查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1830847

2025年全球非病毒基因递送技术市场报告

Non-Viral Gene Delivery Technologies Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，非病毒基因转殖技术市场发展迅速，预计从2024年的39.6亿美元成长到2025年的45.7亿美元，复合年增长率达15.6%。预测期内的增长归因于基因研究的扩展、慢性遗传疾病盛行率的上升、生物技术和製药研发活动的增加、遗传和分子生物学研究的进步以及政府和机构资金的增加。

预计未来几年，非病毒基因递送市场将快速成长，到2029年市场规模将达到80.6亿美元，复合年增长率（CAGR）为15.2%。预测期内的增长可归因于个性化医疗需求的不断增长、其在癌症和罕见疾病研究中的日益普及、CRISPR和其他基因编辑技术的进步、基于mRNA的疗法的快速发展以及细胞疗法和组织工程的持续增长。这段时期的主要趋势包括脂质奈米颗粒和聚合物载体的开发、基于DNA和RNA的疗法的开发及其与人工智慧和计算建模的结合、新一代脂质奈米颗粒（LNP）的出现以及奈米技术的持续进步。

非病毒基因转移技术是指无需依赖病毒作为载体即可将遗传物质导入细胞的方法。这些方法能够实现精准可控的基因递送，同时降低与病毒系统相关的安全风险和免疫反应。其主要目的是改变或调控基因表现，用于治疗遗传性疾病和推进细胞疗法的发展。

非病毒基因转移技术的主要产品类型包括试剂和套件、递送装置以及预拌奈米颗粒。试剂和套件是即用型化学製剂，旨在无需病毒即可将遗传物质递送至细胞内。递送方式多种多样，包括体外、体内和离体，可采用的技术包括电穿孔、脂质体转染、聚合物转染、物理方法（例如显微注射和基因枪）以及奈米颗粒。这些技术可应用于基因治疗、DNA疫苗、 RNA干扰（RNAi）、CRISPR/Cas9基因编辑和蛋白质表现等领域。最终用户包括生物技术和生物製药公司、研究机构和学术机构。

美国在2025年春季突然提高关税及其引发的贸易摩擦对製药公司造成了严重衝击。利润丰厚的学名药生产商尤其脆弱，一些公司不得不缩减低收益药物的生产规模。生物技术公司也因关税导致的专用试剂短缺而面临临床试验延期。为因应这一局面，製药业正在印度和欧洲扩大原料药的生产，增加库存，并游说政府对基本药物给予贸易豁免。

《非病毒基因转移技术市场研究报告》是商业研究公司最新发布的系列报告之一，提供非病毒基因转移技术市场统计数据，例如全球市场规模、区域份额、竞争对手及其市场份额、详细的市场细分、市场趋势和商业机会，为您提供在非病毒基因转移技术行业取得成功所需的数据。本报告透过对产业现状和未来发展趋势的详细分析，为您提供所需的一切资讯。

未来几年，对个人化医疗日益增长的需求预计将推动非病毒基因转移技术市场的成长。个人化医疗是一种医疗保健方法，它根据个人独特的基因组成、生活方式和环境因素，量身定制预防、诊断和治疗方案。基因组定序技术的进步推动了这项需求的成长，该技术能够实现更精准的诊断、标靶治疗，并为每位患者提供更完善、更个人化的治疗效果。非病毒基因转移技术在这一趋势中发挥关键作用，因为它提供了一种更安全、更灵活的方式，可以根据患者的基因谱递送治疗基因，而无需承担病毒载体相关的安全风险。例如，美国非营利组织个人化医疗联盟（Personalized Medicine Coalition）于2024年2月报告称，美国食品药物管理局（FDA）在2023年核准了16种用于治疗罕见疾病患者的新型个人化疗法（2022年批准了6种）。因此，个人化医疗的日益普及正在推动对非病毒基因转移技术的需求。

非病毒基因递送市场的公司也积极探索非病毒基因治疗平台等创新技术，以提高基因治疗的安全性和精准性。这些平台无需病毒即可将治疗性基因或核酸递送至细胞内，从而实现针对多种疾病的精准可控基因治疗，同时降低免疫反应和其他安全隐患的风险。例如，2023年10月，美国生物技术公司Generation Bio宣布推出免疫静止DNA（iqDNA），它是封闭式末端DNA（ceDNA）的改良版本。这种新型DNA能够逃避免疫系统的检测，并且在小鼠和非人灵长类动物中，透过脂质奈米颗粒（LNP）系统给药后，其细胞激素水平和耐受性与化学修饰的mRNA相当。由于其安全性更高，Generation Bio正优先将iqDNA作为其研发项目（包括其领先的A型血友病治疗项目）的主要DNA载体。

2023年9月，美国製药公司SOHM Inc.收购了ABBIE Inc.，具体金额未揭露。 SOHM Inc.是一家专注于学名药和自有品牌药物的製药公司。此次收购巩固了SOHM在非病毒基因转移技术领域的地位，增强了其开发下一代基因编辑解决方案的能力，并扩大了其在基因治疗市场的份额。 ABBIE Inc.是一家总部位于美国的基因编辑平台公司，致力于开发用于基因有效载荷的非病毒载体递送系统。

非病毒基因转移技术市场由提供服务的营业单位所获得的收益所构成，这些服务包括配製遗传物质、开发递送系统和优化转染。市场价值还包括服务供应商销售的任何相关商品的价值，或包含在其服务产品中的任何相关商品的价值。非病毒基因转移技术市场还包括脂质奈米颗粒、聚合物载体、电穿孔装置和显微注射系统的销售。此市场的价值代表“出厂价”，即製造商或生产商销售商品的价值，无论销售对像是其他营业单位（包括下游製造商、经销商和零售商）还是直接销售给最终客户。该市场中的商品价值还包括製造商提供的任何相关服务。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税，以及新冠疫情及其復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球非病毒基因转殖技术：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 终端用户产业分析
  • 全球非病毒基因递送技术市场：成长率分析
  • 全球非病毒基因递送技术市场表现：规模与成长，2019-2024年
  • 全球非病毒基因递送技术市场预测：规模与成长，2024-2029年，2034年
  • 全球非病毒基因递送技术：潜在市场规模 (TAM)

第六章 市场细分

  • 全球非病毒基因递送技术市场：依产品、效能及预测划分，2019-2024年、2024-2029年、2034年
  • 试剂和套件
  • 输送装置
  • 预製奈米颗粒
  • 全球非病毒基因递送技术市场：依递送方式、效能与预测划分，2019-2024年、2024-2029年、2034年
  • 体外
  • 体内
  • 体外
  • 全球非病毒基因递送技术市场：依技术、效能和预测划分，2019-2024年、2024-2029年、2034年
  • 电穿孔
  • 基于脂质的转染
  • 基于聚合物的转染
  • 物理方法（显微注射、基因枪）
  • 奈米颗粒
  • 全球非病毒基因传递技术市场：按应用、效能和预测划分，2019-2024年、2024-2029年、2034年
  • 基因治疗
  • 去氧核糖核酸（DNA）疫苗
  • 核糖核酸干扰（RNAi）
  • 丛集的规律间隔的短回文重复序列（CRISPR）或Cas9基因编辑
  • 蛋白质表现
  • 全球非病毒基因递送技术市场依最终用途、性能及预测划分，2019-2024年、2024-2029年、2034年
  • 生物技术和生物製药公司
  • 研究和学术机构
  • 其他用途
  • 全球非病毒基因递送技术市场：按试剂和套件（按类型）细分、性能和预测，2019-2024年、2024-2029年、2034年
  • 转染试剂
  • 质体去氧核糖核酸（DNA）套件
  • 信使核糖核酸 (RNA) 递送试剂套件
  • 小干扰核糖核酸 (RNA) 递送试剂套件
  • 丛集规律间隔短回文重复序列相关蛋白试剂
  • 细胞特异性递送试剂
  • 全球非病毒基因递送技术市场：按递送装置（类型）、性能和预测进行细分，2019-2024年、2024-2029年、2034年
  • 电穿孔系统
  • 显微注射系统
  • 基因枪或生物弹道输送装置
  • 超音波介导输送装置
  • 动态基因传递系统
  • 全球非病毒基因递送技术市场：按预製奈米颗粒（类型）细分、性能和预测，2019-2024年、2024-2029年、2034年
  • 脂质奈米粒子
  • 聚合物基奈米粒子
  • 金基奈米粒子
  • 基于树状聚合物聚合物的奈米粒子
  • 奈米碳管管基奈米颗粒
  • 无机奈米粒子

第七章 区域和国家分析

  • 全球非病毒基因传递技术市场：按地区、绩效和预测划分，2019-2024年、2024-2029年、2034年
  • 全球非病毒基因递送技术市场：国家、绩效及预测，2019-2024年、2024-2029年、2034年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章：德国市场

第十八章：法国市场

第十九章：义大利市场

第二十章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第三十章：竞争格局与公司概况

  • 非病毒基因递送技术市场：竞争格局
  • 非病毒基因递送技术市场：公司概况
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
    • Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • Boehringer Ingelheim GmbH
  • Agilent Technologies Inc.
  • Lonza Group AG
  • Sartorius AG
  • Bio-Rad Laboratories Inc.
  • Bio-Techne Corp.
  • Takara Bio Inc.
  • GenScript Biotech Corporation
  • Poseida Therapeutics Inc.
  • ElevateBio LLC
  • ProBio Inc.
  • ReCode Therapeutics Inc.
  • Altogen Biosystems Inc.
  • Generation Bio
  • Indee Labs Inc.

第32章 全球市场竞争基准化分析与仪錶板

第33章 重大併购

第34章 近期市场趋势

第35章：高潜力市场国家、细分市场与策略

  • 2029年非病毒基因递送技术市场：提供新机会的国家
  • 2029年非病毒基因递送技术市场：充满新机会的细分市场
  • 2029年非病毒基因递送技术市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章附录

简介目录
Product Code: r37838

Non-viral gene delivery technologies are approaches for transferring genetic material into cells without relying on viruses as carriers. These methods reduce safety risks and immune responses associated with viral systems while allowing for precise and controlled delivery. Their primary purpose is to modify or regulate gene expression for the treatment of genetic disorders and the advancement of cell-based therapies.

The main product categories in non-viral gene delivery technologies include reagents and kits, delivery devices, and pre-formulated nanoparticles. Reagents and kits are ready-to-use chemical formulations designed to introduce genetic material into cells without the use of viruses. Delivery can be achieved through various modes, such as in vitro, in vivo, and ex vivo, using technologies like electroporation, lipid-based transfection, polymer-based transfection, physical methods (e.g., microinjection and gene gun), and nanoparticles. These technologies have applications in gene therapy, DNA vaccines, RNA interference (RNAi), CRISPR/Cas9 gene editing, and protein expression. End users include biotechnology and biopharmaceutical companies, research and academic institutes, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The non-viral gene delivery technologies market research report is one of a series of new reports from The Business Research Company that provides non-viral gene delivery technologies market statistics, including non-viral gene delivery technologies industry global market size, regional shares, competitors with a non-viral gene delivery technologies market share, detailed non-viral gene delivery technologies market segments, market trends and opportunities, and any further data you may need to thrive in the non-viral gene delivery technologies industry. The non-viral gene delivery technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-viral gene delivery technologies market size has grown rapidly in recent years. It will grow from $3.96 billion in 2024 to $4.57 billion in 2025 at a compound annual growth rate (CAGR) of 15.6%. The growth during the historic period can be attributed to the expansion of genetic research, the rising prevalence of chronic genetic disorders, increasing biotechnology and pharmaceutical R\&D activities, advancements in genetic and molecular biology research, and greater government and institutional funding.

The non-viral gene delivery technologies market size is expected to see rapid growth in the next few years. It will grow to $8.06 billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to the rising demand for personalized medicine, increasing adoption in cancer and rare disease research, the advancement of CRISPR and other gene editing technologies, rapid expansion of mRNA-based therapeutics, and the continued growth of cell therapy and tissue engineering. Key trends expected during this period include advancements in lipid nanoparticles and polymer-based vectors, the development of DNA- and RNA-based therapeutics, integration with artificial intelligence and computational modeling, the emergence of next-generation lipid nanoparticles (LNPs), and continued progress in nanotechnology.

The rising demand for personalized medicine is expected to drive the growth of the non-viral gene delivery technologies market in the coming years. Personalized medicine is a healthcare approach that tailors prevention, diagnosis, and treatment to an individual's unique genetic makeup, lifestyle, and environmental factors. This growing demand is fueled by advances in genomic sequencing technologies, which enable more precise diagnoses, targeted therapies, and improved treatment outcomes customized to each patient. Non-viral gene delivery technologies play a key role in this trend, as they provide safer and more flexible methods for delivering therapeutic genes based on a patient's genetic profile, without the safety risks associated with viral vectors. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that the Food and Drug Administration (FDA) approved 16 new personalized therapies for patients with rare diseases in 2023, compared with 6 approvals in 2022. Therefore, the growing adoption of personalized medicine is fueling the demand for non-viral gene delivery technologies.

Companies in the non-viral gene delivery market are also advancing innovations such as non-viral genetic medicine platforms to improve the safety and precision of gene therapies. These platforms deliver therapeutic genes or nucleic acids into cells without using viruses, lowering the risk of immune responses and other safety concerns while enabling controlled and accurate gene therapy for various diseases. For instance, in October 2023, Generation Bio Co., a US-based biotechnology company, introduced immune-quiet DNA (iqDNA), an enhanced version of its closed-ended DNA (ceDNA). This novel DNA avoids innate immune system detection and demonstrated cytokine levels and tolerability comparable to chemically modified mRNA in mice and non-human primates when delivered through its lipid nanoparticle (LNP) system. Due to its improved safety profile, Generation Bio is prioritizing iqDNA as the main DNA cargo across its programs, including its lead hemophilia A treatment.

In September 2023, SOHM Inc., a US-based pharmaceutical company specializing in generic and private-label drugs, acquired ABBIE Inc. for an undisclosed sum. This acquisition strengthens SOHM's position in non-viral gene delivery technologies, enhancing its capacity to develop next-generation gene-editing solutions and expand its footprint in the genetic therapeutics market. ABBIE Inc. is a US-based gene-editing platform company that develops non-viral vector-based delivery systems for genetic payloads.

Major players in the non-viral gene delivery technologies market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Evonik Industries AG, Moderna Inc., Boehringer Ingelheim GmbH, Agilent Technologies Inc., Lonza Group AG, Sartorius AG, Bio-Rad Laboratories Inc., Bio-Techne Corp., Takara Bio Inc., GenScript Biotech Corporation, Poseida Therapeutics Inc., ElevateBio LLC, ProBio Inc., ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.

North America was the largest region in the non-viral gene delivery technologies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in non-viral gene delivery technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the non-viral gene delivery technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-viral gene delivery technologies market consists of revenues earned by entities by providing services such as genetic material formulation, delivery system development, and transfection optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-viral gene delivery technologies market also includes sales of lipid nanoparticles, polymer-based carriers, electroporation devices, and microinjection systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Viral Gene Delivery Technologies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-viral gene delivery technologies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-viral gene delivery technologies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-viral gene delivery technologies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Reagents And Kits; Delivery Devices; Pre-Formulated Nanoparticles
  • 2) By Delivery: In-Vitro; In-Vivo; Ex-Vivo
  • 3) By Technology: Electroporation; Lipid-Based Transfection; Polymer-Based Transfection; Physical Methods (Microinjection, Gene Gun); Nanoparticles
  • 4) By Application: Gene Therapy; Deoxyribonucleic Acid (DNA) Vaccines; Ribonucleic Acid Interference (RNAi); Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing; Protein Expression
  • 5) By End-Use: Biotechnology And Biopharmaceutical Companies; Research And Academic Institutes; Other End-Uses
  • Subsegments:
  • 1) By Reagents And Kits: Transfection Reagents; Plasmid Deoxyribonucleic Acid (DNA) Kits; Messenger Ribonucleic Acid (RNA) Delivery Kits; Small Interfering Ribonucleic Acid (RNA) Delivery Kits; Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents; Cell-Specific Delivery Reagents
  • 2) By Delivery Devices: Electroporation Systems; Microinjection Systems; Gene Guns Or Biolistic Delivery Devices; Ultrasound-Mediated Delivery Devices; Hydrodynamic Gene Delivery Systems
  • 3) By Pre-Formulated Nanoparticles: Lipid-Based Nanoparticles; Polymer-Based Nanoparticles; Gold-Based Nanoparticles; Dendrimer-Based Nanoparticles; Carbon Nanotube-Based Nanoparticles; Inorganic Compound-Based Nanoparticles
  • Companies Mentioned: Thermo Fisher Scientific Inc.; Danaher Corporation; Merck KGaA; Evonik Industries AG; Moderna Inc.; Boehringer Ingelheim GmbH; Agilent Technologies Inc.; Lonza Group AG; Sartorius AG; Bio-Rad Laboratories Inc.; Bio-Techne Corp.; Takara Bio Inc.; GenScript Biotech Corporation; Poseida Therapeutics Inc.; ElevateBio LLC; ProBio Inc.; ReCode Therapeutics Inc.; Altogen Biosystems Inc.; Generation Bio; Indee Labs Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Viral Gene Delivery Technologies Market Characteristics

3. Non-Viral Gene Delivery Technologies Market Trends And Strategies

4. Non-Viral Gene Delivery Technologies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Non-Viral Gene Delivery Technologies Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Non-Viral Gene Delivery Technologies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Non-Viral Gene Delivery Technologies Market Growth Rate Analysis
  • 5.4. Global Non-Viral Gene Delivery Technologies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Non-Viral Gene Delivery Technologies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Non-Viral Gene Delivery Technologies Total Addressable Market (TAM)

6. Non-Viral Gene Delivery Technologies Market Segmentation

  • 6.1. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Reagents And Kits
  • Delivery Devices
  • Pre-Formulated Nanoparticles
  • 6.2. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • In-Vitro
  • In-Vivo
  • Ex-Vivo
  • 6.3. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Electroporation
  • Lipid-Based Transfection
  • Polymer-Based Transfection
  • Physical Methods (Microinjection, Gene Gun)
  • Nanoparticles
  • 6.4. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Gene Therapy
  • Deoxyribonucleic Acid (DNA) Vaccines
  • Ribonucleic Acid Interference (RNAi)
  • Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing
  • Protein Expression
  • 6.5. Global Non-Viral Gene Delivery Technologies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Biotechnology And Biopharmaceutical Companies
  • Research And Academic Institutes
  • Other End-Uses
  • 6.6. Global Non-Viral Gene Delivery Technologies Market, Sub-Segmentation Of Reagents And Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Transfection Reagents
  • Plasmid Deoxyribonucleic Acid (DNA) Kits
  • Messenger Ribonucleic Acid (RNA) Delivery Kits
  • Small Interfering Ribonucleic Acid (RNA) Delivery Kits
  • Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents
  • Cell-Specific Delivery Reagents
  • 6.7. Global Non-Viral Gene Delivery Technologies Market, Sub-Segmentation Of Delivery Devices, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Electroporation Systems
  • Microinjection Systems
  • Gene Guns Or Biolistic Delivery Devices
  • Ultrasound-Mediated Delivery Devices
  • Hydrodynamic Gene Delivery Systems
  • 6.8. Global Non-Viral Gene Delivery Technologies Market, Sub-Segmentation Of Pre-Formulated Nanoparticles, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lipid-Based Nanoparticles
  • Polymer-Based Nanoparticles
  • Gold-Based Nanoparticles
  • Dendrimer-Based Nanoparticles
  • Carbon Nanotube-Based Nanoparticles
  • Inorganic Compound-Based Nanoparticles

7. Non-Viral Gene Delivery Technologies Market Regional And Country Analysis

  • 7.1. Global Non-Viral Gene Delivery Technologies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Non-Viral Gene Delivery Technologies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Viral Gene Delivery Technologies Market

  • 8.1. Asia-Pacific Non-Viral Gene Delivery Technologies Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Viral Gene Delivery Technologies Market

  • 9.1. China Non-Viral Gene Delivery Technologies Market Overview
  • 9.2. China Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Viral Gene Delivery Technologies Market

  • 10.1. India Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Viral Gene Delivery Technologies Market

  • 11.1. Japan Non-Viral Gene Delivery Technologies Market Overview
  • 11.2. Japan Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Viral Gene Delivery Technologies Market

  • 12.1. Australia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Viral Gene Delivery Technologies Market

  • 13.1. Indonesia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Viral Gene Delivery Technologies Market

  • 14.1. South Korea Non-Viral Gene Delivery Technologies Market Overview
  • 14.2. South Korea Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Viral Gene Delivery Technologies Market

  • 15.1. Western Europe Non-Viral Gene Delivery Technologies Market Overview
  • 15.2. Western Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Viral Gene Delivery Technologies Market

  • 16.1. UK Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Viral Gene Delivery Technologies Market

  • 17.1. Germany Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Viral Gene Delivery Technologies Market

  • 18.1. France Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Viral Gene Delivery Technologies Market

  • 19.1. Italy Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Viral Gene Delivery Technologies Market

  • 20.1. Spain Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Viral Gene Delivery Technologies Market

  • 21.1. Eastern Europe Non-Viral Gene Delivery Technologies Market Overview
  • 21.2. Eastern Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Viral Gene Delivery Technologies Market

  • 22.1. Russia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Viral Gene Delivery Technologies Market

  • 23.1. North America Non-Viral Gene Delivery Technologies Market Overview
  • 23.2. North America Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Viral Gene Delivery Technologies Market

  • 24.1. USA Non-Viral Gene Delivery Technologies Market Overview
  • 24.2. USA Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Viral Gene Delivery Technologies Market

  • 25.1. Canada Non-Viral Gene Delivery Technologies Market Overview
  • 25.2. Canada Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Viral Gene Delivery Technologies Market

  • 26.1. South America Non-Viral Gene Delivery Technologies Market Overview
  • 26.2. South America Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Viral Gene Delivery Technologies Market

  • 27.1. Brazil Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Viral Gene Delivery Technologies Market

  • 28.1. Middle East Non-Viral Gene Delivery Technologies Market Overview
  • 28.2. Middle East Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Viral Gene Delivery Technologies Market

  • 29.1. Africa Non-Viral Gene Delivery Technologies Market Overview
  • 29.2. Africa Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Viral Gene Delivery Technologies Market Competitive Landscape And Company Profiles

  • 30.1. Non-Viral Gene Delivery Technologies Market Competitive Landscape
  • 30.2. Non-Viral Gene Delivery Technologies Market Company Profiles
    • 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Non-Viral Gene Delivery Technologies Market Other Major And Innovative Companies

  • 31.1. Boehringer Ingelheim GmbH
  • 31.2. Agilent Technologies Inc.
  • 31.3. Lonza Group AG
  • 31.4. Sartorius AG
  • 31.5. Bio-Rad Laboratories Inc.
  • 31.6. Bio-Techne Corp.
  • 31.7. Takara Bio Inc.
  • 31.8. GenScript Biotech Corporation
  • 31.9. Poseida Therapeutics Inc.
  • 31.10. ElevateBio LLC
  • 31.11. ProBio Inc.
  • 31.12. ReCode Therapeutics Inc.
  • 31.13. Altogen Biosystems Inc.
  • 31.14. Generation Bio
  • 31.15. Indee Labs Inc.

32. Global Non-Viral Gene Delivery Technologies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Viral Gene Delivery Technologies Market

34. Recent Developments In The Non-Viral Gene Delivery Technologies Market

35. Non-Viral Gene Delivery Technologies Market High Potential Countries, Segments and Strategies

  • 35.1 Non-Viral Gene Delivery Technologies Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Non-Viral Gene Delivery Technologies Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Non-Viral Gene Delivery Technologies Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer